FNA (Paragon 28 Inc.) Pangali EV/EBITDA

Paragon 28, Inc. (FNA) generates revenue by supplying advanced implantation systems to orthopedic surgeons and clinics treating lower extremity injuries. High switching costs and FDA patent protection create a robust defensive moat. This price chart, serving as the primary valuation tool with the metric, complements the analysis of the digital planning ecosystem that firmly locks physicians into Paragon 28, Inc. (FNA) solutions.

This indicator determines the business value relative to its operating profit before depreciation, taxes, and interest. Analyzing the EV/EBITDA valuation multiple allows for a comparison of market capitalization and net debt against the actual ability to generate cash flow. For Paragon 28, Inc. (FNA), with its high margins and demand for Apex implants, this metric serves as a critical filter for assessing whether the market is overpaying for rapid revenue growth.